Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760019 · ClinicalTrials.gov registry record · Phase 2
Inflammation and Vascular Function in Atherosclerosis
A Phase 2 study of Atherosclerosis, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00760019: Completed Phase 2 study of Atherosclerosis, sponsored by Brigham and Women's Hospital.
NCT00760019 is a Phase 2 study of Atherosclerosis that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 58 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00760019, a Phase 2 study of Atherosclerosis, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether reducing inflammation in blood vessels with an aspirin-like drug called salsalate will improve blood vessel function.
Primary Outcome
Flow-mediated, endothelium-dependent vasodilation (percentage increase in brachial artery diameter after a 5 minute ischemic stimulus) measured at the end of placebo treatment and end of salsalate treatment were compared.
Conditions Studied
Interventions
- DRUG placebo
- DRUG salsalate
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT00760019 record still lists
NCT00760019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00760019 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00760019 about?
NCT00760019 is a clinical study titled "Inflammation and Vascular Function in Atherosclerosis". The purpose of this study is to determine whether reducing inflammation in blood vessels with an aspirin-like drug called salsalate will improve blood vessel function.
What is the current status of trial NCT00760019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2005-08. Estimated completion is 2011-02.
What conditions does trial NCT00760019 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT00760019?
The interventions under investigation include: placebo (DRUG), salsalate (DRUG).
Who is sponsoring clinical trial NCT00760019?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00760019 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00760019's enrollment target sits among peer trials
58 59th of 69 higher than 11 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Advancing Postmenopausal Preventive Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation
COMPLETED · Phase 2
-
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
COMPLETED · Phase 2
-
An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia